Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Aug 20:3:152.
doi: 10.3389/fphar.2012.00152. eCollection 2012.

Current State and Future Prospects of Direct-to-Consumer Pharmacogenetics

E W Chua  1 , M A Kennedy
Affiliations

Current State and Future Prospects of Direct-to-Consumer Pharmacogenetics

E W Chua et al. Front Pharmacol. .

Abstract

Direct-to-consumer (DTC) DNA testing has grown from contentious beginnings into a global industry, by providing a wide range of personal genomic information directly to its clients. These companies, typified by the well-established 23andMe, generally carry out a gene-chip analysis of single-nucleotide polymorphisms (SNPs) using DNA extracted from a saliva sample. These genetic data are then assimilated and provided direct to the client, with varying degrees of interpretation. Although much debate has focused on the limitations and ethical aspects of providing genotypes for disease risk alleles, the provision of pharmacogenetic results by DTC companies is less studied. We set out to evaluate current DTC pharmacogenetics offerings, and then to consider how these services might best evolve and adapt in order to play a potentially useful future role in delivery of personalized medicine.

Keywords: direct-to-consumer; personal genome; personalized medicine; pharmacogenetics; pharmacogenomics.

PubMed Disclaimer

References

    1. 23andMe (2011). Exome 80x [Online]. San Francisco. Available at: https://www.23andme.com/exome/ [accessed 30 January 2012].
    1. Anonymous (2008). Direct-to-consumer genetic tests: flawed and unethical. Lancet Oncol. 9, 1113.10.1016/S1470-2045(08)70288-2 - DOI - PubMed
    1. Altman R. B. (2011). Pharmacogenomics: “noninferiority” is sufficient for initial implementation. Clin. Pharmacol. Ther. 89, 348–35010.1038/clpt.2010.310 - DOI - PubMed
    1. Black J. L., Walker D. L., O’kane D. J., Harmandayan M. (2012). Frequency of undetected CYP2D6 hybrid genes in clinical samples: impact on phenotype prediction. Drug Metab. Dispos. 40, 111–11910.1124/dmd.111.040832 - DOI - PMC - PubMed
    1. Chung W. H., Hung S. I., Hong H. S., Hsih M. S., Yang L. C., Ho H. C., Wu J. Y., Chen Y. T. (2004). Medical genetics: a marker for Stevens–Johnson syndrome. Nature 428, 486–48610.1038/428486a - DOI - PubMed

LinkOut - more resources